Clinical Aplication of Amiodarone Trials

  • Yoga Yuniadi Divisi Aritmia, Departemen Kardiologi dan Kedokteran Vaskuler FKUI dan Pusat Jantung Nasional Harapan, Kita, Jl S Parman Kav 87 Jakarta 11420


Amiodarone is a class-3 antiarrhythmia drug having a unique pharmaco-kinetic and pharmacodynamic properties. Some trials on amiodarone, from ARREST to ALIVE, showed its efficacy in acute phase or as chronic therapy of tachyarrhytmias. This article reviews clinical application of those trials.


Download data is not yet available.


Somberg JC, Timar S, Bailin SJ, Lakatos F, Haffajee CI, Tarjan J, dkk. Administration of a new aqueous formulation of intravenous amiodarone. Am J Cardiol. 2004; 93: 576 – 81

Gallik DM, Singer I, Meissner MD, Molnar J, Somberg JC. Hemodynamic and surface electrocardiographic effects of a new aqueous formulation of intravenous amiodarone. Am J Cardiol 2002; 90: 964 – 8

Amiodarone Trial Meta-Analysis Investigator. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trial. Lancet. 1997; 350: 1417 – 24

Kudenchuck PJ, Cobb LA, Copass MK, dkk. Amiodarone for Resuscitation after Out-of-hospital Cardiac Arrest due to Ventricle Fibrillation. N Engl J Med. 1999; 341: 871 – 8.

Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6: advanced cardiovascular life support: section 1: introduction to ACLS 2000: overview of recommended changes in ACLS from the guidelines 2000 conference. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 2000;102 (8 suppl):I86-9.

Dorian P, Cass D, Schwartz B, et al. Amiodarone as compared with lidocaine for shock-resistant ventricle fibrillation. N Engl J Med. 2002; 346: 884 – 90

Boutitie F, Boissel JP, Connolly SJ, Camm AJ, Cairns JA, Julian DG, et al. Amiodarone interaction with ß-blockers. Analysis of the merged EMIAT and CAMIAT databases. Circulation. 1999; 99: 2268 – 75

Siddoway LA. Amiodarone: Guidelines for use and monitoring. Am Fam Physician. 2003; 68: 189 – 96.

Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005; 352: 225 – 37.

Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus Implantable Cardioverter-Defibrillator Trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia (AMIOVIRT). J Am Coll Cardiol. 2003; 41: 1707 – 12.

Moss AJ, Zareba W, Hall WJ, et al., for the Multicenter Automatic Defibrillator Implantation Trial II Investigators, Prophylactic Implantation of a Defibrillator in Patients with Myocardial Infraction and Reduced Ejection Fraction. N Engl J Med. 2002; 346: 877 – 83.

Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006; 295: 211 – 3.

Wyse DG, Waldo AL, DiMarco JP, dkk. Atrial Fibrillation Follow-up Investigation of Rhythm Management. A comparison of rate control and rhythm control n patients with atrial fibrillation. N Engl J Med. 2002; 347: 1825 – 33.

Chevalier P, Durand-Dubief A, Burri H, dkk. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: A meta-analysis. J Am Coll Cardiol. 2003; 41: 255 – 62.

Hohnloser SH, Kuck K, Lilienthal J. Rhythm or rate control in atrial fibrillation – Pharmacological Intervention in Atrial Fibrillation (PIAF). Lancet. 2000; 356: 1789 – 94.

Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, dkk. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med. 2000; 342: 13 – 20.

Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN.Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation. 1998; 98: 2574 – 9.

Hilleman DE, Spinler SA. Conversion of recent onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials. Pharmacotherapy 2002; 22: 66 – 74.

Villareal RP, Hariharan R, Liu BC, Kar B, Lee VV, Elayda M, dkk. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol. 2004; 43: 742 – 8.

Guarnieri T, Nolan S, Gottlieb SO, Dudek A, Lowry DR. Intravenous amiodarone for prevention of atrial fibrillation after open heart surgery: the amiodarone reduction in coronary heart (ARCH) trial. J Am Coll Cardiol. 1999; 34: 343 – 7.

Skoularigis J, Rothlisberger C, Skudicky D, Essop MR, Wisenbaugh T, Sareli P. Effectiveness of amiodarone and electrical cardioversion for chronic rheumatic atrial fibrillation after mitral valve surgery. Am J Cardiol. 1993; 72: 423 – 7. Diunduh: 12 Oktober 2009. Diunduh: 12 Oktober 2009.
Views & Downloads
Abstract views: 990   
PDF (Bahasa Indonesia) downloads: 2887   
How to Cite
Yuniadi, Y. (1). Clinical Aplication of Amiodarone Trials. Indonesian Journal of Cardiology, 30(1), 25-31.
Review Article